Annual EBITDA
-$29.20 M
-$1.69 M-6.15%
December 31, 2023
Summary
- As of February 8, 2025, RGLS annual EBITDA is -$29.20 million, with the most recent change of -$1.69 million (-6.15%) on December 31, 2023.
- During the last 3 years, RGLS annual EBITDA has fallen by -$15.75 million (-117.06%).
- RGLS annual EBITDA is now -379.01% below its all-time high of -$6.10 million, reached on December 31, 2011.
Performance
RGLS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$13.97 M
-$3.08 M-28.28%
September 30, 2024
Summary
- As of February 8, 2025, RGLS quarterly EBITDA is -$13.97 million, with the most recent change of -$3.08 million (-28.28%) on September 30, 2024.
- Over the past year, RGLS quarterly EBITDA has dropped by -$3.08 million (-28.28%).
- RGLS quarterly EBITDA is now -1847.98% below its all-time high of -$717.00 thousand, reached on September 30, 2011.
Performance
RGLS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$41.03 M
-$6.34 M-18.26%
September 30, 2024
Summary
- As of February 8, 2025, RGLS TTM EBITDA is -$41.03 million, with the most recent change of -$6.34 million (-18.26%) on September 30, 2024.
- Over the past year, RGLS TTM EBITDA has dropped by -$6.34 million (-18.26%).
- RGLS TTM EBITDA is now -5622.87% below its all-time high of -$717.00 thousand, reached on September 30, 2011.
Performance
RGLS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
RGLS EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -6.2% | -28.3% | -18.3% |
| 3 y3 years | -117.1% | -97.7% | -42.2% |
| 5 y5 years | +33.7% | -192.3% | -202.0% |
RGLS EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -10.2% | at low | -113.7% | at low | -54.9% | at low |
| 5 y | 5-year | -117.1% | at low | -1607.5% | at low | -215.8% | at low |
| alltime | all time | -379.0% | +62.7% | -1848.0% | +35.8% | -5622.9% | +47.6% |
Regulus Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$13.97 M(+28.3%) | -$41.03 M(+18.3%) |
| Jun 2024 | - | -$10.89 M(+31.1%) | -$34.70 M(+13.4%) |
| Mar 2024 | - | -$8.31 M(+5.5%) | -$30.61 M(+4.8%) |
| Dec 2023 | -$29.20 M(+6.2%) | -$7.87 M(+3.1%) | -$29.20 M(+4.7%) |
| Sep 2023 | - | -$7.63 M(+12.3%) | -$27.90 M(+1.0%) |
| Jun 2023 | - | -$6.80 M(-1.6%) | -$27.61 M(-1.0%) |
| Mar 2023 | - | -$6.91 M(+5.2%) | -$27.88 M(+1.3%) |
| Dec 2022 | -$27.51 M(+3.8%) | -$6.57 M(-10.6%) | -$27.51 M(-1.1%) |
| Sep 2022 | - | -$7.34 M(+3.9%) | -$27.82 M(-3.6%) |
| Jun 2022 | - | -$7.07 M(+8.1%) | -$28.86 M(+4.7%) |
| Mar 2022 | - | -$6.54 M(-5.0%) | -$27.57 M(+4.1%) |
| Dec 2021 | -$26.49 M(+96.9%) | -$6.88 M(-17.9%) | -$26.49 M(+29.7%) |
| Sep 2021 | - | -$8.38 M(+45.2%) | -$20.43 M(+57.2%) |
| Jun 2021 | - | -$5.77 M(+5.7%) | -$12.99 M(-4.4%) |
| Mar 2021 | - | -$5.46 M(+567.7%) | -$13.59 M(+1.0%) |
| Dec 2020 | -$13.46 M(-13.4%) | -$818.00 K(-13.3%) | -$13.46 M(-20.4%) |
| Sep 2020 | - | -$943.00 K(-85.2%) | -$16.90 M(-18.5%) |
| Jun 2020 | - | -$6.36 M(+19.4%) | -$20.73 M(+11.0%) |
| Mar 2020 | - | -$5.33 M(+25.1%) | -$18.68 M(+20.3%) |
| Dec 2019 | -$15.53 M(-64.7%) | -$4.26 M(-10.8%) | -$15.53 M(-16.9%) |
| Sep 2019 | - | -$4.78 M(+11.0%) | -$18.68 M(-18.8%) |
| Jun 2019 | - | -$4.31 M(+97.5%) | -$23.00 M(-26.7%) |
| Mar 2019 | - | -$2.18 M(-70.6%) | -$31.37 M(-28.8%) |
| Dec 2018 | -$44.04 M(-34.1%) | -$7.42 M(-18.5%) | -$44.04 M(-11.1%) |
| Sep 2018 | - | -$9.10 M(-28.1%) | -$49.56 M(-10.1%) |
| Jun 2018 | - | -$12.67 M(-14.7%) | -$55.13 M(-12.4%) |
| Mar 2018 | - | -$14.86 M(+14.9%) | -$62.93 M(-5.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2017 | -$66.86 M(-14.7%) | -$12.93 M(-11.9%) | -$66.86 M(-8.1%) |
| Sep 2017 | - | -$14.67 M(-28.4%) | -$72.75 M(-4.7%) |
| Jun 2017 | - | -$20.48 M(+9.0%) | -$76.37 M(-0.0%) |
| Mar 2017 | - | -$18.78 M(-0.2%) | -$76.39 M(-2.5%) |
| Dec 2016 | -$78.38 M(+44.8%) | -$18.82 M(+2.9%) | -$78.38 M(+18.2%) |
| Sep 2016 | - | -$18.29 M(-10.8%) | -$66.34 M(+9.3%) |
| Jun 2016 | - | -$20.50 M(-1.3%) | -$60.68 M(-0.2%) |
| Mar 2016 | - | -$20.77 M(+206.4%) | -$60.80 M(+12.3%) |
| Dec 2015 | -$54.12 M(-1.9%) | -$6.78 M(-46.3%) | -$54.12 M(-21.7%) |
| Sep 2015 | - | -$12.63 M(-38.8%) | -$69.11 M(+4.9%) |
| Jun 2015 | - | -$20.63 M(+46.4%) | -$65.87 M(+15.8%) |
| Mar 2015 | - | -$14.09 M(-35.3%) | -$56.86 M(+3.1%) |
| Dec 2014 | -$55.15 M(+218.9%) | -$21.77 M(+131.8%) | -$55.15 M(+57.8%) |
| Sep 2014 | - | -$9.39 M(-19.2%) | -$34.95 M(+27.8%) |
| Jun 2014 | - | -$11.62 M(-6.1%) | -$27.36 M(+20.4%) |
| Mar 2014 | - | -$12.38 M(+687.7%) | -$22.72 M(+31.4%) |
| Dec 2013 | -$17.30 M(+7.1%) | -$1.57 M(-12.5%) | -$17.30 M(-22.6%) |
| Sep 2013 | - | -$1.79 M(-74.3%) | -$22.35 M(-13.6%) |
| Jun 2013 | - | -$6.98 M(+0.4%) | -$25.88 M(+22.2%) |
| Mar 2013 | - | -$6.95 M(+4.8%) | -$21.18 M(+31.1%) |
| Dec 2012 | -$16.15 M(+164.9%) | -$6.63 M(+24.6%) | -$16.15 M(+45.3%) |
| Sep 2012 | - | -$5.32 M(+133.9%) | -$11.11 M(+70.7%) |
| Jun 2012 | - | -$2.27 M(+18.0%) | -$6.51 M(+53.7%) |
| Mar 2012 | - | -$1.93 M(+21.3%) | -$4.24 M(+83.6%) |
| Dec 2011 | -$6.10 M(-58.6%) | -$1.59 M(+121.8%) | -$2.31 M(+221.8%) |
| Sep 2011 | - | -$717.00 K | -$717.00 K |
| Dec 2010 | -$14.73 M | - | - |
FAQ
- What is Regulus Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Regulus Therapeutics?
- What is Regulus Therapeutics annual EBITDA year-on-year change?
- What is Regulus Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Regulus Therapeutics?
- What is Regulus Therapeutics quarterly EBITDA year-on-year change?
- What is Regulus Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Regulus Therapeutics?
- What is Regulus Therapeutics TTM EBITDA year-on-year change?
What is Regulus Therapeutics annual EBITDA?
The current annual EBITDA of RGLS is -$29.20 M
What is the all time high annual EBITDA for Regulus Therapeutics?
Regulus Therapeutics all-time high annual EBITDA is -$6.10 M
What is Regulus Therapeutics annual EBITDA year-on-year change?
Over the past year, RGLS annual EBITDA has changed by -$1.69 M (-6.15%)
What is Regulus Therapeutics quarterly EBITDA?
The current quarterly EBITDA of RGLS is -$13.97 M
What is the all time high quarterly EBITDA for Regulus Therapeutics?
Regulus Therapeutics all-time high quarterly EBITDA is -$717.00 K
What is Regulus Therapeutics quarterly EBITDA year-on-year change?
Over the past year, RGLS quarterly EBITDA has changed by -$3.08 M (-28.28%)
What is Regulus Therapeutics TTM EBITDA?
The current TTM EBITDA of RGLS is -$41.03 M
What is the all time high TTM EBITDA for Regulus Therapeutics?
Regulus Therapeutics all-time high TTM EBITDA is -$717.00 K
What is Regulus Therapeutics TTM EBITDA year-on-year change?
Over the past year, RGLS TTM EBITDA has changed by -$6.34 M (-18.26%)